Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Therapeutic effects of combined meloxicam and glucosamine sulfate treatment on patients with osteoarthritis, and its effect on serum CTX-U44;, CTX-U45;, COMP and MMP-3

Lu Zhijun¹, Chen Rongchun¹, Lin Feixiang¹, Wu Yaohong¹, Liu Ning¹, Zhang Shufang¹, Zhong Mingliang¹, Zhong Hongfa²

¹Department of Spinal Surgery; ²Department of Trauma, People's Hospital of Ganzhou City, Jiangxi Province, China.

For correspondence:- Zhong Hongfa Email: ft1192@163.com

Accepted: 16 June 2019 Published: 29 July 2019

Citation: Zhijun L, Rongchun C, Feixiang L, Yaohong W, Ning L, Shufang Z, et al. Therapeutic effects of combined meloxicam and glucosamine sulfate treatment on patients with osteoarthritis, and its effect on serum CTX-U44;, CTX-U45;, COMP and MMP-3. Trop J Pharm Res 2019; 18(7):1553-1557 doi: 10.4314/tjpr.v18i7.28

© 2019 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To study the therapeutic influence of meloxicam-glucosamine sulfate combination in patients with osteoarthritis and their effect on serum CTX-I, CTX-II, COMP and MMP-3.

Methods: A total of 88 patients with osteoarthritis were assigned to control (n = 44) and treatment groups (n = 44), using the random number table method. Control group was given 7.5 mg of meloxicam, while treatment group received 0.5 g of glucosamine sulfate capsule in addition to meloxicam. Both groups were treated continuously for 8 weeks. Serum levels of C-terminal telopeptide of type I collagen (CTX-I), C-terminal telopeptide of type II collagen (CTX-II), cartilage oligomeric matrix protein (COMP) and matrix metalloproteinase-3 (MMP-3) were compared for the two groups after treatment.

Results: Lysholm score significantly increased in the two groups after treatment. Serum CTX-I, CTX-II, COMP and MMP-3 in the two groups were significantly lower than before treatment, but the reductions were more pronounced in the treatment group (p < 0.05). During treatment, mild vomiting and pruritus of the skin appeared in both groups, but these were relieved after symptomatic treatment without any serious adverse reactions.

Conclusion: Treatment with a combination of meloxicam and glucosamine sulfate produces significant beneficial effects in patients with osteoarthritis by reduction of clinical symptoms, pain relief and reduction of serum CTX-I, CTX-II, MMP-3 and COMP.

Keywords: Meloxicam, Glucosamine sulfate, Osteoarthritis, MMP-3, CTX-I, COMP, CTX-II